Company Overview of Altor BioScience Corporation
Altor BioScience Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of immunotherapeutic agents for the treatment of cancer, viral infections, and inflammatory and autoimmune diseases. Its product candidates include ALT-801, a T-cell receptor-targeted immunotherapeutic for cancer; ALT-836, a monoclonal antibody-based tissue factor antagonist treatment of patients with acute respiratory distress syndrome and acute lung injury; and ALT-803, an IL-15 superagonist for patients with solid and hematological tumors/metastatic melanoma. The company’s product candidates also include ALT-802, a p53-TCR (T-cell receptors)/IgG1 fusion protein for treat...
2810 North Commerce Parkway
Miramar, FL 33025-3958
Founded in 2002
Key Executives for Altor BioScience Corporation
Founder, Chief Executive Officer, President and Director
Vice Chairman and Chief Business Officer
Vice President of Research and Development
Consulting Medical Director and Member of Clinical Advisory Board
Compensation as of Fiscal Year 2016.
Altor BioScience Corporation Key Developments
Altor BioScience Corporation Partners with National Cancer Institute to Further Develop Altor’s ALT-803 and ALT-801 Cancer Immunotherapeutics
Apr 11 16
Altor BioScience Corporation announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), an Institute of the National Institutes of Health (NIH). Under the CRADA, Altor will work with NCI to further develop its proprietary Interleukin-15 (IL-15) superagonist ALT-803 and single-chain T-cell-receptor/Interleukin-2 (IL-2) fusion protein ALT-801. In addition to the research to be conducted with NCI via this CRADA, these cytokine-based immunotherapy candidates are currently in various, unassociated Phase I and Phase II clinical trials for hematologic and solid tumor cancers.
Altor BioScience Corporation Announces Board Appointments
Apr 7 16
Altor BioScience Corporation announced that it has named Dr. Patrick Soon-Shiong, a well-known physician scientist and inventor of Abraxane as Chairman of the company’s Board of Directors. Mr. Fred Middleton, Managing Director of Sanderling Ventures, the company’s former Chairman and also the former CFO of Genentech, becomes Vice Chairman and will serve as the company’s Chief Business Officer. While continuing to serve on the company’s board, Mr. Middleton will take on an important strategic and operational role in leading the company’s business development activities. Dr. Soon-Shiong serves as Chairman of the Chan Soon-Shiong Family Foundation and Chairman and CEO of the Chan Soon-Shiong Institute of Molecular Medicine and Chairman and CEO of NantKwest. He currently co-chairs the CEO Council for Health and Innovation at the Bipartisan Policy Center and is a member of the Global Advisory Board of Bank of America.
Altor BioScience Corporation Presents at BIO-Europe 2015, Nov-02-2015
Oct 1 15
Altor BioScience Corporation Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 6, 2016
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries